Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011
Tue, June 7, 2011
Mon, June 6, 2011
Sat, June 4, 2011
Fri, June 3, 2011
Thu, June 2, 2011
Wed, June 1, 2011
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011
Tue, May 17, 2011
Mon, May 16, 2011
Sun, May 15, 2011
[ Sun, May 15th 2011 ] - Market Wire
Teva to Acquire Taiyo
Fri, May 13, 2011
Thu, May 12, 2011

Anacor Pharmaceuticals Announces Retirement of Zhi Hong from Board of Directors


//health-fitness.news-articles.net/content/2011/ .. irement-of-zhi-hong-from-board-of-directors.html
Published in Health and Fitness on Wednesday, May 25th 2011 at 18:40 GMT by Market Wire   Print publication without navigation


PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Zhi Hong, Ph.D., has retired from its Board of Directors effective May 25, 2011. Dr. Hong has been a member of the Anacor Board of Directors since 2009. Dr. Hong is the Senior Vice President and Head of the Infectious Disease Center of Excellence for Drug Discovery at GlaxoSmithKline (GSK).

"Our relationship with GSK has been exceptionally productive, and Zhi has been a major supporter of our collaboration."

aOn behalf of the Board and the Company, we would like to thank Zhi for the many contributions he has made at Anacor,a said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. aOur relationship with GSK has been exceptionally productive, and Zhi has been a major supporter of our collaboration.a

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds, including its three lead programs currently in development: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and atopic dermatitis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit [ http://www.anacor.com ].


Publication Contributing Sources